Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Novavax, Inc. NVAX
$8.57
-$0.31 (-3.62%)
На 18:00, 12 мая 2023
+1 930.34%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
784302185.00000000
-
week52high
76.77
-
week52low
5.61
-
Revenue
1598951000
-
P/E TTM
-1
-
Beta
1.70761200
-
EPS
-7.68000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | Outperform | 09 авг 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 08 июн 2022 г. |
| B of A Securities | Underperform | 20 мая 2022 г. | |
| B. Riley Securities | Buy | Buy | 26 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 мар 2022 г. |
| JP Morgan | Underweight | Neutral | 22 сент 2022 г. |
| B. Riley Securities | Buy | Buy | 14 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 02 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jacobs John C | A | 249590 | 249590 | 23 янв 2023 г. |
| Jacobs John C | A | 290700 | 290700 | 23 янв 2023 г. |
| Trizzino John | D | 1600 | 1600 | 14 дек 2022 г. |
| Trizzino John | D | 6922 | 773 | 14 дек 2022 г. |
| Trizzino John | A | 7695 | 1600 | 14 дек 2022 г. |
| Erck Stanley C | D | 6967 | 6966 | 14 дек 2022 г. |
| Erck Stanley C | D | 36492 | 2320 | 14 дек 2022 г. |
| Erck Stanley C | A | 38812 | 6966 | 14 дек 2022 г. |
| Glenn Gregory M | D | 3100 | 3100 | 14 дек 2022 г. |
| Glenn Gregory M | D | 8009 | 1033 | 14 дек 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| CAPITAL FUND MANAGEMENT S.A. | 654100 | 362404 | 30 сент 2022 г. |
| Vanguard Total Stock Market Index Fund | 1678850 | -17876 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 1252380 | 35872 | 31 авг 2020 г. |
| SPDR S&P Biotech ETF | 1217400 | -62624 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 824030 | -4432 | 31 июл 2020 г. |
| Vanguard Small-Cap Index Fund | 740928 | -4340 | 31 июл 2020 г. |
| Franklin Templeton Investment Funds -Biotechnology Discovery | 508300 | -369600 | 31 июл 2020 г. |
| Vanguard Small-Cap Value Index Fund | 447323 | -315 | 31 июл 2020 г. |
| Franklin Biotechnology Discovery Fund | 445800 | -263800 | 31 июл 2020 г. |
| Franklin U.S. Opportunities Fund (Lux) | 471364 | 471364 | 30 июн 2020 г. |
Новостная лента
Short-Squeeze Stocks Alert: CVNA, NVAX Make Most-Shorted Stocks List
InvestorPlace
11 мая 2023 г. в 15:32
Fueling the flames of speculative fervor, business news agency CNBC released its list of the most heavily shorted public securities. Topping the list stood used-car retailer Carvana (NYSE: CVNA ).
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View
Zacks Investment Research
10 мая 2023 г. в 13:41
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
Is the Worst Over for Novavax?
The Motley Fool
10 мая 2023 г. в 13:30
Novavax is cutting costs and restructuring to stay afloat as vaccine demand declines. As part of that effort, the company plans on cutting 25% of its workforce.
Layoffs Misery Continues In Tech With LinkedIn, Intel And Novavax All Axing Roles
Forbes
10 мая 2023 г. в 08:05
The layoffs are all at least in the hundreds, and cite difficult economic times as the reason.
Novavax stock surges amid earnings miss, 25% workforce reduction announcement
Yahoo Finance
09 мая 2023 г. в 17:48
Yahoo Finance health care reporter Anjalee Khemlani details Novavax's latest earnings report.